Active	Status	Sponsor type	Region	Phase	Filter
4 Active 3 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
GEOFFROIS, Lionnel
TAS-120-203, NCT04601857 / 2020-000945-15: Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma	Active, not recruiting	2	43	Europe, US	futibatinib and pembrolizumab (KEYTRUDA®)), TAS120 and MK-3475-B04	Taiho Oncology, Inc., Merck Sharp & Dohme LLC	Advanced and Metastatic Urothelial Cancer	03/24	08/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
GEOFFROIS, Lionnel
TAS-120-203, NCT04601857 / 2020-000945-15: Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma	Active, not recruiting	2	43	Europe, US	futibatinib and pembrolizumab (KEYTRUDA®)), TAS120 and MK-3475-B04	Taiho Oncology, Inc., Merck Sharp & Dohme LLC	Advanced and Metastatic Urothelial Cancer	03/24	08/25